| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/16/2009 | CA2452217C Hiv inhibiting pyrimidines derivatives |
| 06/16/2009 | CA2415154C Modified release formulations of selective serotonin re-uptake inhibitors |
| 06/16/2009 | CA2405136C Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents |
| 06/16/2009 | CA2340898C Compositions and methods for treating intracellular infections |
| 06/16/2009 | CA2330500C Pharmaceutical compositions capable of being gelled |
| 06/16/2009 | CA2304975C Stabilized preparations for use in metered dose inhalers |
| 06/16/2009 | CA2266439C Neutrokine .alpha. |
| 06/11/2009 | WO2009073683A2 Methods of treating copd |
| 06/11/2009 | WO2009073146A2 Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| 06/11/2009 | WO2009073139A2 Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit |
| 06/11/2009 | WO2009072629A1 Skin external preparation |
| 06/11/2009 | WO2009072598A1 Therapeutic agent for pruritus |
| 06/11/2009 | WO2009072132A2 Beta glycolipids for the treatment of calcification related degenerative disorders |
| 06/11/2009 | WO2009072086A1 Methods of and combination therapies for treating or delaying the onset of dyskinesia |
| 06/11/2009 | WO2009071993A2 Pharmaceutical compositon for cleansing of the bowel |
| 06/11/2009 | WO2009071625A1 Mequitazine for treating or preventing pathologies involving histamine h4 receptors |
| 06/11/2009 | WO2009071099A1 Elevation of the plasma hdl-cholesterol level |
| 06/11/2009 | WO2009071094A2 Combination treatment of ischemic effects |
| 06/11/2009 | WO2009049230A3 Microsphere-based materials with predefined 3d spatial and temporal control of biomaterials, porosity and/or bioactive signals |
| 06/11/2009 | WO2005112567A9 Vaginal microbicide |
| 06/11/2009 | WO2002099058A3 KCNMAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 06/11/2009 | US20090151013 Modified ES cells and ES cell-specific genes |
| 06/11/2009 | US20090149502 a mixture of 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one and an adrenergic agonist selected from the group consisting of albuterol, terbutaline, fenoterol, formoterol and salmeterol, used for the treatment of allergies, skin and respiratory system disorders |
| 06/11/2009 | US20090149473 Topical antifungal composition |
| 06/11/2009 | US20090149453 Methods and compositions for treating bacterial infections and diseases associated therewith |
| 06/11/2009 | US20090149413 RORS as Modifiers of the p21 Pathway and Methods of Use |
| 06/11/2009 | US20090149391 Novel antimicrobial bolisin peptides |
| 06/11/2009 | US20090148855 Nucleic acid encoding or targeting sodium channel scn3a alpha subunits |
| 06/11/2009 | US20090148533 Ion binding compositions |
| 06/11/2009 | US20090148511 Composition and method for dermatological treatment |
| 06/11/2009 | US20090148459 Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other Agents |
| 06/11/2009 | US20090148457 Hepatocyte growth factor receptor antagonists and uses thereof |
| 06/11/2009 | US20090148444 Pharmaceutical composition for treating immune diseases |
| 06/11/2009 | US20090148413 Method for treatment of irritable bowel syndrome |
| 06/11/2009 | US20090148410 Improving the health of a companion animal; reducing pathogenic bacteria in feces, reducing stress, autoimmune disease, aging, kidney stones |
| 06/11/2009 | US20090148409 For improving the health of a companion animal; reducing pathogenic bacteria in feces, reducing stress, autoimmune disease, aging, kidney stones |
| 06/11/2009 | CA2708065A1 Therapeutic agent for pruritus |
| 06/11/2009 | CA2708030A1 Composition |
| 06/11/2009 | CA2707823A1 A stable docusate pharmaceutical composition |
| 06/11/2009 | CA2706898A1 Mequitazine for treating or preventing pathologies involving histamine h4 receptors |
| 06/11/2009 | CA2706883A1 Methods of treating copd |
| 06/10/2009 | EP2067792A2 Inhibitory antibodies of HER3 activity |
| 06/10/2009 | EP2067784A2 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivates as anti-flammatory agents |
| 06/10/2009 | EP2067486A1 Use of CD23 antagonists for the treatment of neoplastic disorders |
| 06/10/2009 | EP2066355A2 Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
| 06/10/2009 | EP2066328A2 Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |
| 06/10/2009 | EP2066327A2 Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
| 06/10/2009 | EP2066323A2 Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein |
| 06/10/2009 | EP2066302A2 Stabilizing compositions for antibiotics and methods of use |
| 06/10/2009 | EP1414797B9 Hepatitis c virus polymerase inhibitors with a heterobicylic structure |
| 06/10/2009 | EP1319003B1 Xanthine phosphodiesterase v inhibitors |
| 06/10/2009 | EP1289573B1 A medicinal aerosol antidiabetics formulation |
| 06/10/2009 | EP0831892B1 Multimeric, recombinant urease vaccine |
| 06/10/2009 | EP0732924B1 Tts containing a parasympathomimetic and a parasympatholytic agent |
| 06/10/2009 | CN101450934A Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| 06/10/2009 | CN101450211A Composite antihypertensive preparation |
| 06/10/2009 | CN100497628C Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 06/10/2009 | CN100497610C Polypeptides encoded by human lipase-like gene and composition, and methods of utilizing same |
| 06/10/2009 | CN100497604C Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| 06/10/2009 | CN100497389C Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| 06/10/2009 | CN100497388C Antibody selective for tumor necrosis factor-related apoptosis-inducing ligand receptor and use thereof |
| 06/10/2009 | CN100497386C Antibodies of non-functional P2X7 receptor and its uses |
| 06/10/2009 | CN100497385C Antibodies of non-functional P 2 Chi 7 receptor and its uses of diagnosis and treatment of cancers and other syndrome |
| 06/10/2009 | CN100497346C Chemokine CCR5 receptor modulators |
| 06/10/2009 | CN100497334C Indole derivatives useful as histamine h3 antagonists |
| 06/10/2009 | CN100496607C Combination of a NSAID and a PDE-4 inhibitor |
| 06/10/2009 | CN100496606C Composite preparation containing nitrate esters medicine and HMG-CoA reductase inhibitor |
| 06/10/2009 | CN100496501C Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist |
| 06/10/2009 | CN100496485C Antineoplastic combinations |
| 06/10/2009 | CN100496472C Topical compositions and methods for treating pain |
| 06/09/2009 | US7545964 Methods and devices for quantitative analysis of x-ray images |
| 06/09/2009 | US7544788 Isolated nucleic acid molecule encoding a neurotrophic growth factor |
| 06/09/2009 | US7544684 Hydrazono-malonitriles |
| 06/09/2009 | US7544664 Sequences facilitating penetration of a substance of interest |
| 06/09/2009 | US7544655 Novel amino acid sequences are within the carboxy termini of fibrinogen; useful for cell culture and cell separation |
| 06/09/2009 | US7544519 Identifying modulators for prevention and treatment of infection, blood, metabolic, cell proliferative and respiratory system disorders |
| 06/09/2009 | US7544510 Stem cells of the islets of Langerhans and their use in treating diabetes mellitus |
| 06/09/2009 | US7544497 Modulating sirtuin deacetylase protein; apoptosis; using flavone, stilbene, isoflavone, sphingosine; stroke; cardiovascular disorders; antiarthritic agents; Alzheimer's disease |
| 06/09/2009 | US7544480 drug screening an antagonist which inhibits hydroxylation of hypoxia inducible factor or an agonist which promotes hydroxylation of hypoxia inducible factor; hydroxylation of asparagine; antitumor agent; use for radiotherapy or chemotherapy |
| 06/09/2009 | US7544374 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 06/09/2009 | US7544365 TRPV1+ sensory neurons control of β-cells stress and islet inflammation in diabetes |
| 06/09/2009 | US7544364 reduced tissue accumulation of the glycopeptide antibiotic, reduced nephrotoxicity and reduced histamine release; side effect reduction |
| 06/09/2009 | US7544363 Exhibit probiotic activity in aerobic conditions; does not contribute to the production of future generation of antibiotic resistant pathogens |
| 06/09/2009 | US7544358 Bacterial sepsis, hemorrhagic shock, toxic inhalation, and bleomycin and other drug-induced lung injury; fibronectin and tenascin receptor antagonist; cancer |
| 06/09/2009 | US7544357 Administering an interferon antagonist and a FMS-like tyrosine kinase 3 ("Flt3") ligand antagonist, such as an anti-IFN-alpha antibody; in vitro assay for determining risk for developing an autoimmune disease |
| 06/09/2009 | US7544301 Citrate-based dialysate chemical formulations |
| 06/09/2009 | CA2481005C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy |
| 06/09/2009 | CA2438141C Noninvasive measurements of chemical substances |
| 06/09/2009 | CA2403721C Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 06/09/2009 | CA2401812C Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 06/09/2009 | CA2371554C Pharmaceutical composition comprising an angiotensin ii antagonist for preventing, treating or development-inhibiting simple retinopathy and preproliferative retinopathy |
| 06/09/2009 | CA2350659C Pharmaceutical composition for modified release insulin sensitiser |
| 06/09/2009 | CA2317443C Agent for treating allergic or hypersensitivity condition |
| 06/09/2009 | CA2276183C Pharmaceutical preparations of glutathione and methods of administration thereof |
| 06/04/2009 | WO2009070639A1 Method of increasing immunological effect |
| 06/04/2009 | WO2009070378A1 Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
| 06/04/2009 | WO2009070328A1 Modulators of the epidermal growth factor receptor (egfr) pathway for use in the treatment or prevention of substance abuse |
| 06/04/2009 | WO2009069828A1 Agent for improving motor complications or psychiatric symptoms in parkinson's disease |
| 06/04/2009 | WO2009069355A1 Method for screening of therapeutic agent for allergic airway inflammation and/or airway hypersensitivity using il-17rb-positive nkt cell |
| 06/04/2009 | WO2009068906A2 Combinations comprising zd4054 and a src family kinase inhibitor 172 |